Nebido Testosterone undecanoate uses, dose and side effects

All of these people that fit within these descriptions should not use Nebido injections as a treatment for any condition. To start the treatment, your doctor or medical professional will administer Nebido slowly into one of the muscles in the body. This is usually done in the ventrogluteals, deltoid, or another dense muscle area. The Nebido type of injection is very strong and will last for a while, making it more convenient to use Nebido injections than some other types of TRT injections. The active substance is testosterone undecanoate 250mg/ml (corresponding to 157.9 mg testosterone).

If your testosterone levels are high, your doctor may decide to give you injections less often. Athletes treated for testosterone replacement in primary and secondary male hypogonadism should be advised that the medicinal product contains an active substance which may produce a positive reaction in anti-doping tests. In patients suffering from severe cardiac, hepatic or renal insufficiency or ischaemic heart disease, treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure. Once injected intramuscularly (usually into the buttocks), NEBIDO forms a deposit at the injection site. The testosterone undecanoate slowly breaks down and releases testosterone into the bloodstream through a process called lymphatic absorption.

what nebido is and what it is used for

Treatment with high doses of testosterone preparations commonly may reversibly stop or reduce sperm production (see also under “Possible side effects” ). Treatment with high doses of testosterone preparations commonly may reversibly stop or reduce sperm production (see also under “Possible side effects”). Ingestion of Nebido 1000mg/4 ml, or the contents of any of the Nebido 1000mg/4 ml (Nebido 1000mg/4 ml (transdermal)) products will not result in clinically significant serum Nebido 1000mg/4 ml concentrations due to extensive first-pass metabolism.

• hypersensitivity to the active substance or to any of the excipients (listed in section 6.1). You must be over 38, have had your ovaries removed or have suffered with premature menopause to warrant further hormone tests. You may have low testosterone depending on the symptoms you have, please contact us to find out how we can help. Nebido contains 2000 mg benzyl benzoate in each 4 ml vial which is equivalent to 500 mg/ml.

Book a FREE consultationWith Balance My Hormones.

Testosterone and derivatives have been reported to increase the activity of coumarin derived oral anti-coagulants.-Patients receiving oral anti-coagulants require close monitoring, especially at the beginning or end of androgen therapy. Increased monitoring of the prothrombin time, and INR determinations, are recommended. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur in men using Nebido, a liver tumour should be included in the differential-diagnostic considerations. No formal studies have been performed in patients with hepatic impairment. The use of Nebido is contraindicated in men with past or present liver tumours (see section 4.3). After the administration of radio-labelled testosterone, about 90% of the radioactivity appears in the urine as glucuronic and sulphuric acid conjugates and 6% appears in the faeces after undergoing enterohepatic circulation.

The patient should therefore be observed during and immediately after each injection in order to allow for early recognition of possible signs and symptoms of pulmonary oily microembolism. As with all oily solutions, Nebido must be injected strictly intramuscularly and very slowly. Suspected anaphylactic reactions after Nebido injection have been reported.

• Care should be taken to inject Nebido deeply into the gluteal muscle following the usual precautions for intramuscular administration.
• These reactions may occur during or immediately after the injection and are reversible.
• Mark, a 52-year-old construction worker, had been experiencing fatigue, low libido, and difficulty sleeping for several months.
• Nebido is not indicated for use in children and adolescents and it has not been clinically evaluated in males under 18 years of age (see section 4.4).
• Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited.
• Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Seek urgent medical attention if you experience one of these symptoms. The active steroids in USA substance is testosterone undecanoate 250 mg/ml (corresponding to 157.9 mg testosterone). One ampoule / vial contains 1000 mg testosterone undecanoate (corresponding to 631.5 mg testosterone).

Other adverse events reported during the study were headache (6%), dizziness (6%), back pain, pain, nausea, and pustular rash (1% each). RxReasoner is an online resource that provides extensive knowledge about medicines and offers clinical decision support services. With its user-friendly interface and constantly updated database, it is a valuable tool for healthcare professionals who seek to stay informed and provide the highest quality of care to their patients. By using or accessing any part of the website, you are agreeing to the posted terms and policies. The injection interval should always be within the recommended range of 10 to 14 weeks. Special care will be taken to avoid injection into a blood vessel (see “Administration”).

This medicine is not for use in treating low Nebido 1000mg/4 ml without certain medical conditions or due to getting older. Nebido 1000mg/4 ml is a naturally occurring sex hormone produced in a man’s testicles. Small amounts of Nebido 1000mg/4 ml are also produced in a woman’s ovaries and adrenal system.

There is no need for your doctor to adjust the dose if you are over 65 (see “Medical examination/follow up”). Sex hormones are known to facilitate the development of certain tumours induced by known carcinogenic agents. The most appropriate MedDRA term to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well. Nebido is not indicated for use in women and must not be used in pregnant or breast-feeding women, see section 4.3.